- C4 Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- C4 Therapeutics Inc To Discuss CFT7455 Phase 1 Update Call TranscriptDec 12, 2023
- C4 Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- C4 Therapeutics Inc at Wells Fargo Targeted Protein Degradation Summit (Virtual) - Panel Discussion TranscriptFeb 21, 2023
- C4 Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- C4 Therapeutics Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- C4 Therapeutics Inc at Bank of America Precision Oncology Conference TranscriptOct 03, 2022
- C4 Therapeutics Inc To Discuss CFT7455 Cohort Clinical Data Call TranscriptApr 08, 2022
- C4 Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- C4 Therapeutics Inc CFT8919 Pre-Clinical Data Call TranscriptJun 07, 2021
- C4 Therapeutics Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- C4 Therapeutics Inc at UBS Global Healthcare Virtual Conference TranscriptMay 26, 2021
- C4 Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
C4 Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Okay. We'll get started. I'm Eric Joseph, Senior Biotech Analyst with JPMorgan. Our next presenting company is C4 Therapeutics and presenting on behalf of the company CEO, Andrew Hirsch. We'll be doing Q&A after the presentation in the room and for those viewing on the digital conference book, feel free to submit questions via the portal. So with that, Andrew.
Great. Thanks, Eric, and thanks for JPMorgan for having us here today. It's very exciting to actually be here in person and not presenting from my living room, which we did last year. I'm really excited to provide an update on the progress we've made at C4 Therapeutics over the past year, and we have upcoming in store for 2023.
But before I begin, I'll be making forward-looking statements, and this is our disclaimer on that matter, subject to risks and uncertainties that are outlined in the risk factors in our SEC statement. So C4
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)